Review Article

Oral cancer chemoprevention: COX-2 inhibitor a covenant

Shashi Keshwar1*, Sonal Grover2, Daya Shankar3, Deependra Prasad Sarraf4

1Department of Oral Pathology, College of Dental Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
2Department of Oral Pathology and Microbiology, Christian Dental College, Ludhiana, Punjab, India
3Primary Health Center, Parsa, Bihar, India
4Department of Clinical Pharmacology and Therapeutics, B.P. Koirala Institute of Health Sciences, Dharan, Nepal

Received: 25 January 2021
Accepted: 04 March 2021

*Correspondence:
Dr. Shashi Keshwar,
E-mail: keshwar.shashi@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Oral cancer survival remains poor despite advancement in treatment modalities. In oral cancer and oral premalignant lesions, cyclooxygenase-2 (COX-2) is widely expressed and tends to be enhanced especially in high-risk oral lesions. Numerous researches suggests that the inflammation pathway of cyclooxygenase/prostaglandin E2 (PGE2) leads to the development and progression of a number of cancers, including oral squamous cell carcinoma (OSCC). With an emphasis on research data, this article discusses the relationship between inflammation and cancer, summarizes the use of anti-inflammatory agents COX-2 inhibitors for cancer chemoprevention and treatment, and explains the mechanisms underlying the anti-cancer effects of anti-inflammatory agents (COX-2 inhibitors).

Keywords: COX-2 inhibitor; Inflammation, Oral cancer

INTRODUCTION

About 354,864 new cases of oral cancer are detected with 177,384 death annually worldwide.1 Prognosis at the early stage of oral cancer is significantly better as compared to an advanced stage with metastasis.2 Oral cancer is a morbid disease. The five-year survival rate is less than 50%. It is more prevalent in lower socioeconomic communities where tobacco habit is prevalent among people.3 Numerous reviews have outlined interesting and fascinating evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) have promise as anticaner drugs. It has been shown experimentally that nonsteroidal anti-inflammatory drugs stimulate apoptosis and inhibit angiogenesis, two mechanisms that help to suppress malignant transformation and tumor growth.4-6 In present review, we have focused discussion on role of cyclooxygenase-2 inhibitors in oral cancer chemoprevention.

COX-2 INHIBITORS

COX-2 inhibitors are categories of NSAIDs which are generally used as analgesic, antipyretic and anti-inflammatory agents since a very long time. Recently found that these drugs can also be used for cancer prevention and treatment.7,8 COX-2 inhibitors are isoforms of COX inhibitors. COX-2 enzymes are generally absent in normal tissue; however, they are extensively produced in inflammation and cancerous tissue. COX-2 inhibitors selectively target COX-2 and hence it produces much lower toxicity than the traditional NSAIDs.8,9 Other advantages of using COX-2 inhibitors include easy application and relatively low cost through oral administration on an outpatient basis.10 Studies confirmed that NSAIDs have a remarkable inhibitory effect on the growth of oral squamous cell carcinoma (OSCC). Treatment with NSAIDs instigate a remarkable dose and time dependent cell growth reduction.
accompanied by an increase in apoptosis. The exact mechanism of COX-2 inhibitors in cancer inhibition is not clearly understood but these COX-2 inhibitors have multiple mechanism of action in reducing carcinogenesis like upregulation of apoptosis, reduction in inflammation mediators, suppression of mutagens synthesis, inhibition of neo-angiogenesis.

CANCER AND INFLAMMATION

Twenty percent of cancers are initiated by chronic inflammation or persistent infections. Inflammation is a response of the body like a defence that is initiated because of any tissue injury of any nature via numerous releases of inflammatory mediators. Variety of inflammatory mediators like prostaglandins (PG), COX enzyme, matrix metalloproteinases (MMPs) and cytokines can lead to genetic and epigenetic alterations that can lead to alteration in tumor suppressor genes through post-translational modifications and DNA methylation. Cancer cells can express cytokines that recruit neutrophils and macrophages. These cells then release more inflammatory molecules that can lead to amplification of the inflammatory response. Tumor growth can also physically damage the normal tissue which in turn activates the production of damage-associated molecular patterns (DAMPs) that triggers resident granulocytes receptors and it initiates inflammation. The tumor growth can compress lymphatics and blood vessels leading to less nutrient and oxygen supply. Tobacco smoke can cause cancer as it has the ability to cause chronic inflammation and production of reactive oxygen species (ROS). Chronic inflammation is affected by variety of the factor’s interleukins, nitrogen metabolites, oxygen and growth factors. Many factors not only induce the inflammation and repair, but can also lead to cancer concatenation.

COX-2 is expressed in OSCC and the surrounding lymphocytic infiltrates that points towards the fact that there is connection between inflammation and carcinogenesis. Oral dysplastic lesions and OSCC has increased level of COX-2 as compared to the oral hyperplastic epithelium, pointing towards, COX-2 is involved in the early stages of oral carcinogenesis. COX-2 is rarely expressed in normal epithelium but it is highly expressed in cancer and dysplastic cells. Excessive expression of COX-2 in OSCC enhance the release of PGE2. COX-2 is linked with OSCC metastases. COX-2 and PGE2 also cause enhance migration and upregulation of intercellular adhesion molecule-1 (ICAM-1) in the oral squamous cell carcinoma.

Cyclooxygenase-2 also helps in prognosis of the OSCC. Poor disease-free survival is seen in high expression of COX-2 level. Role of inflammation in OSCC also supported by the finding of the study that showed benefit to cancer patients when anti-inflammatory medications have been combined with cancer therapy like combination of celecoxib with cetuximab cause reduction in migration and invasion of oral squamous cell carcinoma.

COX-2 INHIBITORS IN CANCER PREVENTION

Cancer chemoprevention is the use of pharmacological agents to suppress, prevent or reverse the carcinogenesis process. COX-2 inhibitors have exhibited a potential role in various studies that it can help in the prevention of breast, skin, colon and other cancers. COX-2 is connected in tumorigenesis in various tissues like head and neck tumors. COX-2 is considered to contribute in carcinogenesis by inhibiting apoptosis, stimulating cell proliferation and enhancing angiogenesis. That is why, cancer preventive and treatment strategies are using COX-2 inhibitors as potential medication.

COX-2 inhibitors cause reduction in the rate of growth of established tumors in preclinical studies. Studies done on rats indicates that COX-2 inhibitors reduce the incidence and multiplicity of oral dysplasia and carcinomas. This shows the chemo-preventive ability of COX-2 inhibitors by inhibiting cell proliferation activity. In a study done on cultured oral SCC cells, inhibitory effect on PGE2 production and growth of the carcinoma cell lines was found by COX-2 inhibitors. A study on rat tongue cancer revealed that administration of NSAIDs reduced the incidence of squamous cell carcinoma in animals to 23-31% as to compared 71% in untreated controls.

COX-2 overexpression leads to rise in the level of antiapoptotic protein bcl-2 that can lead to survival of damaged cells that is resistant to apoptosis and causing tumorigenesis. A study done by Shiff et al showed that NSAIDs induce apoptosis in colon cancer. Various studies showed a correlation between COX-2 level and angiogenesis with increased production of vascular-endothelial growth factor (VEGF). VEGF level increased in progression from dysplasia to carcinoma. The inhibition of COX cause decreased angiogenesis and reduced tumor invasiveness and metastasis. In a nude mouse model of oral cancer COX-2 inhibitors have shown delay in cell growth and volume of tumor by reducing neo-angiogenesis. That gives a proof of COX-2 inhibitors chemo-preventive action. COX-2 inhibitors may forestall carcinogenesis by influencing other non-COX, non-PG-related sub-molecular components.

CONCLUSION

Various mechanism by which COX and PG add to carcinogenesis have been distinguished, including the restraint of apoptosis, modulation of inflammation and immunosuppression, expanded angiogenesis and invasion and transformation of procarcinogens to cancer-causing agents. COX-2 inhibitors, induce apoptosis, reduce cell proliferation, and inhibit angiogenesis helps in chemoprevention. Further research is needed in this subject.
ACKNOWLEDGEMENTS

The authors would like to thanks Dr. Pramendra Gupta.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

2. Global facts on tobacco or oral health. World Health Organization, Geneva, 2018. Available at: http://www.who.int/oral_health/publications/fact_sheet_tobacco/en/index1.html. Accessed on 22nd October, 2020.

3. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological Typing of Cancer and Pre-cancer of the Oral Mucosa, Ed. 2, Berlin, Germany: Springer-Verlag, 1997:21-6.

4. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90(20):1529-36.

5. Taketo M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90(21):1609-20.

6. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342(26):1960-8.

7. Hawkey CJ. COX-2 inhibitor. Lancet. 1999;353(9149):307-14.

8. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawke E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-52.

9. Goldstein JL, Silverstein FE, Agrawal NM. Reduced risk of upper gastrointestinal ulcer complications with Celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95(7):1681-90.

10. Noble SC, King DS, Olutade JJ. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician. 2000;61(12):3669-76.

11. Nikitakis NG, Hebert C, Lopes MA, Reynolds MA, S auk JJ. PPA Rgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 2002;98(6):817-23.

12. Jackel EC, Raja S, Tan J, Das SK, Dey SK, G riord DA et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, peroxisome proliferators-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(10):1253-59.

13. Kawamori T, Rao CV, Seihbert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58(3):409-12.

14. Masterrell JL, Leahy KM, Koki AT, Zweifel BS. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306-11.

15. Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173-96.

16. Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):e1370.

17. Bonavita E, Galdiero MR, Jaillon S, Mantovani A. Phagocytes as corrupted policemen in cancer-related inflammation. Adv Cancer Res. 2015;128:141-71.

18. Chauhan VP, Martin JD, Liu H, Lacreor DA, Jain SR, Kozin SV et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.

19. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA. 2012;109(38):15101-8.

20. Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015;39(11):1137-45.

21. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-30.

22. Evrovic BM, Pelzmann M, Turhani D, Pammer J, Niederberger V, Neuchrist C et al. Differential expression pattern of cyclooxygenase-1 and -2 in head and neck squamous cell carcinoma. Acta Otolaryngol. 2003;123(8):950-3.

23. Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, de Abreu MC et al. Nuclear factor kappa B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol. 2013;17(1):45-50.

24. Shibata M, Kodani I, Osaki M, Araki K, Adachi H, Ryou K. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol. 2005;41(3):304-12.

25. Seyedmajidi M, Shafaee S, Siadati S, Khorasani M, Bijani A, Ghase mi N. Cyclooxygenase-2 expression in oral squamous cell carcinoma. J Cancer Res Ther. 2014;10(4):1024-9.

26. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto DJ, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 2010;46(12):880-7.

27. Yang SF, Chen MK, Hsieh YS, Chung TT, Hsieh YH, Lin CW, et al. Prostaglandin E2/E2 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem. 2010;285(39):29808-16.

28. Byatnal AA, Byatnal A, Sen S, Guddattu V, Solomon MC. Cyclooxygenase-2-An Imperative
Prognostic Biomarker in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. Pathol Oncol Res. 2015;21(4):1123-31.
29. Pannone G, Sanguedolce F, De Maria S, Farina E, Lo Muzio L, Serrico R et al. Cyclooxygenase isozymes in oral squamous cell carcinoma: A real-time RT-PCR study with clinicopathological correlations. Int J Immunopathol Pharmacol. 2007;20(2):317-24.
30. Qian M, Qian D, Jing H, Li Y, Ma C, Zhou Y. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2014;32(4):1681-8.
31. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcin. 1999;25(4):231-40.
32. Harris RE, Alshafie GA, Abou-Issa H. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60(8):2101-03.
33. Grabbs CJ, Lubet RA, Koki AT. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60(20):5599-602.
34. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP et al. Cyclooxygenase-2 expression up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):9991-4.
35. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev. 1994;13(3-4):303-8.
36. Tsuji M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):705-16.
37. Leahy KM, Koki AT, Masferre JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7(11):1163-70.
38. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramanaiak K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract (review). Ann N Y Acad Sci. 2001;952:109-15.
39. Yamamoto K, Kitayama W, Denda A, Morisaki A, Kuniyasu H, Kirita T. Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in rats initiated with 4-nitroquinoline 1-oxide. Cancer Lett. 2003;199(2):121-9.
40. Yoshida K, Tanaka T, Kohno H, Sakata K, Kawamori T, Mori H et al. A COX-2 inhibitor, nimesulide, inhibits chemically-induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol. 2003;18(1):39-48.
41. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase-2 selective inhibitor NS398 inhibits proliferation of oral carcinoma cells lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9(5):1885-97.
42. Tanaka T, Nishikawa A, Morishita Y, Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett. 1989;48(3):177-82.
43. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell. 1995;83(3):493-501.
44. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Investig. 1995;96(1):491-503.
45. Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferators-activated receptor delta with head and neck squamous cell carcinoma. Arch Otalaryngol. Head Neck Surg. 2001;127(10):1253-9.
46. Gallo O, Franchi A, Magnelli L, Sardi L, Boddi V, Chiarugi V et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61.
47. Chen YJ, Jin YT, Shieh DB, Tsai ST, Wu L. W. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol. 2002;38(7):699-702.
48. Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cells. 1998; 93(5):705-15.
49. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada L, Kitayama J et al. Inhibition of hematogenous metastasis of colon cancer in mice by a selective Cox-2 inhibitor, JTE522. Br J Cancer. 1999;81(8):1274-9.
50. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cells. Laryngoscope. 2002;112(5):839-43.
51. Soh JW, Weinstein IB. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res. 2003;37:261-85.

Cite this article as: Keshwar S, Grover S, Shankar D, Sarraf DP. Oral cancer chemoprevention: COX-2 inhibitor a covenant. Int J Sci Rep 2021;7(4):253-6.